Human immunodeficiency virus (HIV) infection is associated with a profound impairment of T cell function. Hence, enhancement of T cell reactivity to viral and bacterial antigens is important in the treatment of patients with AIDS. To develop tools for amplifying T cell reactivity, we have immunized mice with human helper T cell clones and selected monoclonal antibodies (MAbs) that enhance in' vitro blastogenic responses. MAb NDA5, which recognizes the leukocyte common antigen CD45, amplifies human T'cell responses to mitogens and soluble antigens including'HIV-1 glycoprotein (gp)-120 and peptides derived from the HIV-1 gp.120 sequence. In the presence of MAb NDA5, peripheral blood mononuclear cells (PBMC) from healthy, HIV-1-seronegative individuals displayed augmented blastogenic responses to HIV-1 gp-120 and to.HIV-1 gp-120 synthetic peptides. In vitro memory responses to various vaccines and to alloantigens were also enhanced in cultures with MAb. Similarly, the response of PBMC from AIDS patients to pokeweed mitogen, HIV-1 gp-120, and tetanus toxoid was enhanced with MAb NDA5. The finding' that the in vitro immune response of patients with AIDS can be amplified with MAb NDA5, suggests that the in vivo immune response of immunodeficient individuals can also be enhanced. (J. Clin. Invest. 1990. 85:746-756.) adjuvants human immunodeficiency virus glycoprotein-120 -leukocyte common antigen CD45
Introduction
The acquired immunodeficiency syndrome (AIDS) is characterized immunologically by depletion and functional impairment of the leukocyte common antigen (LCA)l CD4-positive T lymphocyte subset. CD4-positive T lymphocytes are critical to the induction of cell-mediated immunity and control of viral infection. The induction ofprotective immunity in AIDS patients may depend on restoring T cell immunocompetence.
Therefore, a particularly attractive approach to anti-human immunodeficiency virus (HIV) therapy may reside in the enhancement of cellular immune responses. To develop tools for amplifying T cell reactivity, we have immunized mice with human helper T cell clones and selected monoclonal antibodies (MAbs) that enhance in vitro blastogenic responses. In this report we describe the amplification effects displayed by a new MAb, which we named MAb NDA5, on human T cell responses to HIV-l glycoprotein (gp)-120, peptides derived from HIV-1 gp-120, and to other soluble antigens.
A series of lymphoid differentiation antigens were recently shown to serve as signal transducers that control T cell proliferation (1) (2) (3) (4) (5) (6) . These differentiation antigens' and some of the biologically active MAbs that recognize them offer routes whereby enhancement ofcell-mediated immune responses can be attained. Some of these antigens, such as CD3 (gp5O) and CD28 (gp44), are T lineage-specific (7-10), whereas others, including CD I lb (LFA-la), CD18 (LFA-1fl), CD43 (gp-95), CD44 (gp-65-85), CD45 (LCA or T200), and CD45R (restricted LCA or T220), are shared by most cells of hematopoietic origin (1) (2) (3) (4) (5) (6) (11) (12) (13) (14) (15) (16) (17) . In solution, MAbs to CD2, CD3, and CD8 'inhibit T cell proliferation (1, 2) , whereas when immobilized to a solid phase, they initiate T cell proliferation (14) . Antibodies against'CD28, CD43, and CD44 in soluble form have been shown to enhance T cell proliferative responses to recall antigens, alloantigens, and plant mitogens by delivering early progression signals (3, 4, 9-t4) . The specific function of these cell membrane glycoproteins and the mechanism underlying the amplification effect are not clearly understood. The LCA, representing a family of glycoproteins that are major components at the surface ofall lymphoid and myeloid cells, is defined by the CD 45/45R cluster of MAbs. The various CD45 antibodies have been categorized as MAbs which (a) inhibit proliferation of T cells but do not induce aggregation, (b) inhibit proliferation and enhance aggregation, (c) do not affect proliferation, but enhance aggregation,' and (d) enhance both proliferation and aggregation (3, 15) . Few MAbs belonging to the latter category have been described so far. Their amplification effects have been documented in a system in which T cells were triggered to proliferate by the use of anti-CD3 MAbs and
Methods
Generation of murine MAb NDA5. This antibody was generated, as previously described (18) , by immunizing a BALB/c mouse with a human alloreactive T cell clone exhibiting helper function. Briefly, human T cells primed in mixed lymphocyte cultures against HLA-D half-identical stimulating cells were cloned by limiting dilutions. Clones were expanded in medium containing IL-2 and irradiated PBL from the original stimulator. The functional characteristics of the clones were determined as previously described (18). Splenocytes, from the hyperimmunized mouse, were fused with NS-1 plasmocytoma cells using the method of Kohler and Milstein (19) . Hybridoma supernatants were screened for antibody activity by immunofluorescence cytofluorometry using lymphoid and nonlymphoid cell lines as targets as previously described (20) (21) (22) (24) . Synthetic peptides corresponding to segments of HIV-1 gp-120 were kindly supplied by Dr. R. Neurath from the New York Blood Center. Experiments in which the blastogenic response to these peptides and other antigens were compared, were performed using as antigen-presenting cells autologous monocytes pulsed with antigen as described (25) . Mixed lymphocyte cultures were performed using equal numbers (1 X showed a decrease in the percentage of reactive cells and fluorescence intensity at the peak of the blastogenic response on day 6 or day 2, respectively ( Fig. 1 ). NDA5 can be distinguished from other antigens shared by various cells of hematopoietic origin such as CD29, CD38, CD43, CD1 8, and CD1 1A, yet its tissue distribution and level of expression appears to be similar to that of CD45 (26) . Repeated attempts to analyze the molecule recognized by MAb NDA5 by immunoprecipitation of cell membrane lysates labeled with 125I or labeled metabolically with [35S]methionine were inconclusive probably due to the IgM nature of the antibody. Thus, to establish whether MAb NDA5 does indeed react with CD45, its immunoreactivity with transfected mouse cell lines that express different isoforms of CD45 was tested (27) . MAb NDA5 reacted in a pattern that suggests that it recognizes an epitope expressed on each CD45 isoform (Schlossman, S., personal communication).
Cell aggregation studies. MAb NDA5, or its F(ab')2 fragment, induced the aggregation of T cells, B cells, and of mixtures of T and B lymphocytes in plates incubated for 18 h at 25°C or 37°C. No aggregates were found within the first 2 h of incubation with MAb NDA5. The aggregation triggering effect of MAb NDA5 is dose dependent since both the size and the number of cell aggregates were higher at 1 ,g/ml than at 0.5 ,ug/ml. This effect was inhibited at 4°C and in the presence of sodium azide, indicating that it is dependent on cell metabolism. Homotypic cell aggregates resembled rosettes which under the optimal testing conditions (incubation at 37°C with 1 ,ug MAb NDA5/ml) contained 8-20 T MAb NDA5 (0.250-1.00 ,ug/ml) in its native form elicited a strong amplification of the response to PWM. The F(ab')2 fragment of MAb NDA5 at equivalent concentrations was also stimulatory, although slightly less efficient than the native pentamer. The other anti-CD45 MAbs were slightly inhibitory at the concentrations tested (Table II) . Repeat experiments yielded the same results. Thus, the F(ab')2 fragment of MAb NDA5 has a similar biological activity as its parent IgM, indicating that the enhancing effect of this antibody is not isotype dependent.
To establish whether MAb NDA5 acts on the cells at the time of activation or after they have received the proliferation signal, the MAbs were added to PBMC together with PWM (time 0), after 4 h, and after 24 h. Quantitation of the blastogenic response on day 3 showed that the amplification effect occurred only in cultures to which MAb NDA5 was added at initiation (Table III) . A similar amplification effect was also observed when PBMC were incubated with MAb NDA5 (5 ,ug/ml) for 1 h at room temperature, washed four times, and then stimulated with PWM. The day 3 response was significantly augmented compared with cultures incubated in MOPC 104E (Table III) . These results suggest that MAb NDA5 enhances T cell activation and that its effect occurs before IL-2 receptors are being expressed.
It was not clear, however, from these experiments whether the amplification effect is mediated by T cells, since B cells also participate in the PWM response. Furthermore, it was ofinterest to determine whether MAb NDA5 amplifies the direct (CD3-Ti-mediated) and/or alternative pathway of T cell activation. The direct or "antigen pathway" of activation, is initiated by the binding of the appropriate ligand to the CD3-TcR complex, while the alternative pathway is initiated via a number of cell surface molecules other than the antigen receptor. MAb NDA5 amplifies the direct pathway of activation since in each offour repeat experiments, it augmented, at least twofold, the blastogenic response of purified T cells to soluble anti-CD3 MAb in the presence of adhering cells. MAb NDA5 also enhanced the response of purified T cells to 12-O-tetradecanoylphorbol-13-acetate (TPA)/ionomycin (Fig. 3) . Similar to the results obtained in the PWM system, the response to PHA was both accelerated and augmented in the presence of MAb NDA5, compared with cultures with no antibody or with MAb MOPC 104E (Fig. 3) .
To establish whether the amplification effect results from an increase in frequency of cells expressing the receptor for (4) . However, under these culture conditions, the blastogenic response to HIV-1 gp-120 could still be detected in both these individuals.
Since this data suggested that MAb NDA5 augmented both primary and secondary in vitro responses, we explored the possibility of using MAb NDA5 for amplifying the reactivity of T lymphocytes from healthy individuals to synthetic peptides corresponding to different amino acid sequences of HIV-1 gp-120. Hepatitis B vaccine was included as'a control for secondary response and PPD for a primary response. The in vitro blastogenic response was quantitated on days 3,5, and 7. was no primary reactivity to peptides 477-508. In control cultures with MOPC-104E there was no primary reactivity to PPD and only borderline reactivity to one'of the peptides, although there was a progressive increase in the reactivity to HIV-1 gp-120. The "secondary" response to hepatitis B vaccine, with which this women had been immunized, increased rapidly from day 3 to 5 and plateaued on day 7, in the absence of MAb NDA5. In cultures with MAb NDA5 a much higher peak was reached on day 5 after which the response declined in a pattern characteristic of a secondary response. The kinetics of these responses are consistent with the possibility that MAb NDA5 amplifies both primary and secondary T cells responses. We next established whether MAb NDA5 enhances the response of patients with AIDS to HIV-l gp-120. In these experiments cryopreserved PBM (I X 105 cqlls) from two AIDS patients and two healthy controls were stimulated in triplicate wells of 96-well trays with HIV-I 'gp-120 or tetanus toxoid, in the presence or in the absence of MAb NDA5 (Table  V) . To increase the number of antigen presenting cells, irradiated (3,000 rads) HLA-D homozygous lymphoblastoid B cell lines (HTC-LBCL) (5 X 104 cells per well) expressing one of the responder's HLA-D antigens were added to the cultures. The HLA phenotype of patients, controls, and LBCL was characterized by serologic typing to insure compatibility between responding cells and HTC-LBCL for HLA-DR and DQ antigens.
In the presence of MAb NDA5 there was augmentation of the response exhibited by PBMC from healthy individuals to HIV-l gp-120 and to tetanus toxoid. This amplification effect was observed both in cultures with and without HTC-LBCL.
In cultures without MAb NDA5, PBMC from AIDS patients showed no detectable reactivity to HIV-1 gp-120 or tetanus toxoid, even when HTC-LBCL were present. However, addition of MAb NDA5 to cultures containing soluble antigens and HTC-LBCL enhanced the blastogenic responses above the levels seen in cultures in which the patients' PBM were exposed to HTC-LBCL only.
Since the patients reactivity to HIV-l gp-120 and tetanus toxoid could not be evidenced in the absence of MAb NDA5, this antibody may enhance reactivity to soluble antigens by increasing the contact between responding T cells and antigen presenting cells (Table V) .
The possibility of enhancing memory responses which have been induced in vitro was explored using the primed lymphocyte test. For this, PBM from an HLA-DW4/DW6 heterozygous individual were stimulated in primary MLC with an equal number of irradiated PBMC from a DW2/DW4 heterozygote. Small T lymphocytes were collected after 10 d and rechallenged' in secondary cultures with irradiated cells from the specific, primary stimulator and from controls with different HLA-D/DR antigens. The memory response to the specific stimulator used for primary in vitro sensitization was significantly higher in the presence of MAb NDA5, than in cultures without antibody or with MAb MOPC-104E. The potentiating effect of MAb NDA5 was already evident after 24 h and could still be seen after 48 and 72 h (Table VI) . As expected for primary in vitro allorecognition, the response to the DW2-negative control showed a slower progression. The enhancing effect of MAb NDA5 on this primary reaction, became detectable only after 72 h. The primed lymphocytes maintained the ability to discriminate between specific and control stimulators in the presence of MAb NDA5, suggesting that this antibody acted specifically on the lymphocyte clones engaged in the memory response. Thus, virgin as well as memory T lymphocytes are susceptible to the potentiating effect of MAb NDA5 when stimulated with allogeneic HLA-D/DR antigens.
To determine whether MAb NDA5 stimulates the proliferation of T lymphoblasts in the absence of any antigen, we added the antibody to IL-2-dependent normal and malignant T cell clones and to IL-2-independent leukemic T We have demonstrated the MAb NDA5 enhances the primary in vitro response to PPD, HIV-1 gp-120, and derived peptides in normal individuals. PBMC from HIV-infected individuals are also susceptible to the enhancing effects of MAb NDA5. In the presence of MAb NDA5, the blastogenic response of T lymphocytes from these patients to HIV-I gp-120 was significantly increased, suggesting that the signal transducing mechanisms in these cells are still functional. The possibility exist that HIV infection of T cells alters the ability of LCA to efficiently transduce proliferation signals, yet this alteration may be reversed in the presence of MAb NDA5.
Regardless ofthe mechanism involved in the amplification effect displayed by MAb NDA5, its efficiency in stimulating the proliferative response of lymphocytes from AIDS patients is of particular importance. The fact that many patients' responsiveness was greatly enhanced, in spite of their inverted CD4/CD8 ratio, suggests that their depressed immunoreactivity may be manipulated in a clinically beneficial manner. Attempts to vaccinate immunologically deficient patients against viral or bacterial antigens might have a better chance ofsuccess if the generation of effector cells from resting precursors could be enhanced. This could be accomplished by increasing T cell adhesion to antigen-presenting cells and/or intra and intercellular transmission of activation signals. In this context, our observation that MAb NDA5 enhances specific immune responses raises the possibility of using such reagents as adjuvants for active immunization procedures.
The finding that MAb NDA5 amplifies primary and secondary T cell responses to a variety of antigens such as HIV-I gp-120 presents the opportunity of studying cognitive responses to T cell epitopes of HIV with low immunogenicity.
